Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies

Although chimeric antigen receptor T cell immunotherapy has been successfully applied in patients with hematological malignancies, several obstacles still need to be overcome, such as high relapse rates and side effects. Overcoming the limitations of CAR-T cell therapy and boosting the efficacy of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xinping, Jin, Xin, Zhang, Xiaomei, Utsav, Paudel, Zhang, Yi, Guo, Ruiting, Lu, Wenyi, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Leukemia (PH Wiernik, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992085/
https://www.ncbi.nlm.nih.gov/pubmed/36701037
http://dx.doi.org/10.1007/s11864-023-01049-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992085/
https://www.ncbi.nlm.nih.gov/pubmed/36701037
http://dx.doi.org/10.1007/s11864-023-01049-4

Ejemplares similares